MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy [0.03%]
microRNA作为调控癌症药物抗性的重要因子：化疗、靶向治疗、放疗和免疫疗法的新视野与未来方向
Michael Attathikhun,Ancuta Jurj,George A Calin
Michael Attathikhun
Cancer therapy remains an active field of investigation, particularly in understanding and overcoming therapy resistance. Small non-coding RNAs, such as microRNAs (miRNAs), are emerging as key regulators of cancer survival, progression, pro...
Osimertinib acquired resistance among patients with EGFR-mutated NSCLC: from molecular mechanisms to clinical therapeutic strategies [0.03%]
奥西替尼耐药的EGFR突变非小细胞肺癌患者的分子机制及临床治疗策略
Ren Wang,Yuanhang Chen,Liping Li et al.
Ren Wang et al.
Non-small-cell lung cancer (NSCLC) remains the leading cause of global cancer-related mortality. NSCLC patients with epidermal growth factor receptor (EGFR) mutations benefit substantially from treatment with EGFR tyrosine kinase inhibitors...
Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies [0.03%]
解构头颈部癌症对免疫检查点抑制剂产生耐药性的机制并结合综合疗法提高疗效
Wenchao Zhao,Qingqing Luo,Bowen Yuan et al.
Wenchao Zhao et al.
Head and neck squamous cell carcinoma (HNSCC), which arises from the mucosal linings of the oral cavity, pharynx, and larynx, represents the most prevalent head and neck malignancy. This cancer is notable for its elevated incidence and subs...
Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma [0.03%]
克服耐药性：融合阴性的横纹肌肉瘤治疗新策略
Silvia Codenotti,Francesco Marampon,Francesca Megiorni et al.
Silvia Codenotti et al.
Rhabdomyosarcomas (RMS) are aggressive pediatric soft tissue tumors. The fusion-negative subtype (FN-RMS) is characterized by RAS pathway mutations and genomic instability. While standard chemotherapies - vincristine, actinomycin D, and alk...
Overcoming cancer drug resistance through small-molecule targeting of HSP90 and HSP70 [0.03%]
通过小分子靶向HSP90和HSP70克服癌症药物耐药性
Ren-Duan Cai,Ming-Jing Lin,Qing-Mei Ye
Ren-Duan Cai
Heat shock proteins (HSPs) play a critical role in cancer progression and drug resistance by stabilizing oncoproteins, enhancing DNA repair, and modulating apoptosis pathways. In particular, HSP90 and HSP70 have been implicated in maintaini...
Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies [0.03%]
癌症治疗中抗体药物偶联物抗性机制：分子基础和治疗策略
Yue Hao,Zhengbo Song
Yue Hao
Antibody-drug conjugates (ADCs) have emerged as a transformative class in oncology, integrating the target specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule payloads. By harnessing tumor-specific antigen re...
Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update [0.03%]
靶向肿瘤引流淋巴结以克服癌症免疫治疗的耐药性：最新研究进展
Jianan Lu,Jiangnan Yu,Tuo Xu et al.
Jianan Lu et al.
Immune checkpoint inhibitor (ICI) resistance often stems from intratumoral T cell dysfunction. This review focuses on both tumor-intrinsic and tumor-draining lymph node (TDLN)-centric resistance mechanisms. We detail how specific defects wi...
RCC1 knockdown sensitizes drug-resistant colorectal cancer to 5-fluorouracil or doxorubicin by impairing DNA repair [0.03%]
RCC1敲低通过抑制DNA修复使耐药结直肠癌对氟尿嘧啶或阿霉素敏感化
Jing Li,Ya Meng,Xumei Ouyang et al.
Jing Li et al.
Aim: This study aimed to elucidate the role of regulator of chromosome condensation 1 (RCC1) in colorectal cancer (CRC) progression, as well as its involvement in chemoresistance. We specifically examined how RCC1 knockdown modulates cellul...
Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer [0.03%]
新型FAK抑制剂可通过抑制非小细胞肺癌生长和逆转EGFR-TKI耐药性发挥作用
Geng Xu,Camilla Pecoraro,Mahrou Vahabi et al.
Geng Xu et al.
Aim: The current study aims to investigate the critical role of the focal adhesion kinase (FAK) oncogenic signaling pathway in mediating drug resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) and e...
Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: another brick in the wall? [0.03%]
肾细胞癌酪氨酸激酶抑制剂耐药研究进展——再添一砖？
Zirui Dong,Shoukang Li,Mingfeng Li et al.
Zirui Dong et al.
Renal cell carcinoma (RCC), the predominant form of kidney cancer, accounts for 90% of cases and poses significant clinical challenges due to frequent late-stage or metastatic presentation. Based on literature and surveillance data from 202...